Short Interest in Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Decreases By 84.1%

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) saw a large drop in short interest during the month of July. As of July 31st, there was short interest totaling 55,796 shares, a drop of 84.1% from the July 15th total of 350,806 shares. Based on an average daily trading volume, of 2,500 shares, the days-to-cover ratio is presently 22.3 days.

Analyst Ratings Changes

Separately, Danske began coverage on Hansa Biopharma AB (publ) in a research note on Tuesday, June 16th. They set a “buy” rating for the company. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy”.

Hansa Biopharma AB (publ) Price Performance

HNSBF opened at $3.70 on Wednesday. Hansa Biopharma AB has a 52-week low of $2.90 and a 52-week high of $3.70. The firm’s fifty day simple moving average is $3.04 and its two-hundred day simple moving average is $2.95.

Hansa Biopharma AB (publ) Company Profile

Hansa Biopharma AB (publ) is a clinical‐stage biopharmaceutical company headquartered in Lund, Sweden, focused on the development and commercialization of precision immunomodulatory therapies for rare diseases. The company’s proprietary platform centers on highly specific bacterial enzymes that selectively cleave immunoglobulin G (IgG) antibodies, offering a novel approach to desensitization and immunomodulation in transplant and autoimmune settings.

The lead asset, imlifidase (Idefirix), is an enzyme therapeutic designed to rapidly inactivate donor‐specific antibodies in highly sensitized kidney transplant patients.